These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 32404506)

  • 1. ACTRIIA-Fc rebalances activin/GDF versus BMP signaling in pulmonary hypertension.
    Yung LM; Yang P; Joshi S; Augur ZM; Kim SSJ; Bocobo GA; Dinter T; Troncone L; Chen PS; McNeil ME; Southwood M; Poli de Frias S; Knopf J; Rosas IO; Sako D; Pearsall RS; Quisel JD; Li G; Kumar R; Yu PB
    Sci Transl Med; 2020 May; 12(543):. PubMed ID: 32404506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sotatercept analog improves cardiopulmonary remodeling and pulmonary hypertension in experimental left heart failure.
    Joshi SR; Atabay EK; Liu J; Ding Y; Briscoe SD; Alexander MJ; Andre P; Kumar R; Li G
    Front Cardiovasc Med; 2023; 10():1064290. PubMed ID: 36910526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Selective Transforming Growth Factor-β Ligand Trap Attenuates Pulmonary Hypertension.
    Yung LM; Nikolic I; Paskin-Flerlage SD; Pearsall RS; Kumar R; Yu PB
    Am J Respir Crit Care Med; 2016 Nov; 194(9):1140-1151. PubMed ID: 27115515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sotatercept analog suppresses inflammation to reverse experimental pulmonary arterial hypertension.
    Joshi SR; Liu J; Bloom T; Karaca Atabay E; Kuo TH; Lee M; Belcheva E; Spaits M; Grenha R; Maguire MC; Frost JL; Wang K; Briscoe SD; Alexander MJ; Herrin BR; Castonguay R; Pearsall RS; Andre P; Yu PB; Kumar R; Li G
    Sci Rep; 2022 May; 12(1):7803. PubMed ID: 35551212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy.
    Morvan F; Rondeau JM; Zou C; Minetti G; Scheufler C; Scharenberg M; Jacobi C; Brebbia P; Ritter V; Toussaint G; Koelbing C; Leber X; Schilb A; Witte F; Lehmann S; Koch E; Geisse S; Glass DJ; Lach-Trifilieff E
    Proc Natl Acad Sci U S A; 2017 Nov; 114(47):12448-12453. PubMed ID: 29109273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitory Antibodies against Activin A and TGF-β Reduce Self-Supported, but Not Soluble Factors-Induced Growth of Human Pulmonary Arterial Vascular Smooth Muscle Cells in Pulmonary Arterial Hypertension.
    Kudryashova TV; Shen Y; Pena A; Cronin E; Okorie E; Goncharov DA; Goncharova EA
    Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30274147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activin receptor signaling: a potential therapeutic target for osteoporosis.
    Lotinun S; Pearsall RS; Horne WC; Baron R
    Curr Mol Pharmacol; 2012 Jun; 5(2):195-204. PubMed ID: 21787285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Signal transduction pathway through activin receptors as a therapeutic target of musculoskeletal diseases and cancer.
    Tsuchida K; Nakatani M; Uezumi A; Murakami T; Cui X
    Endocr J; 2008 Mar; 55(1):11-21. PubMed ID: 17878607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone morphogenetic protein (BMP) type II receptor deletion reveals BMP ligand-specific gain of signaling in pulmonary artery smooth muscle cells.
    Yu PB; Beppu H; Kawai N; Li E; Bloch KD
    J Biol Chem; 2005 Jul; 280(26):24443-50. PubMed ID: 15883158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone morphogenetic proteins.
    Chen D; Zhao M; Mundy GR
    Growth Factors; 2004 Dec; 22(4):233-41. PubMed ID: 15621726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of receptors and signaling pathways for orphan bone morphogenetic protein/growth differentiation factor ligands based on genomic analyses.
    Mazerbourg S; Sangkuhl K; Luo CW; Sudo S; Klein C; Hsueh AJ
    J Biol Chem; 2005 Sep; 280(37):32122-32. PubMed ID: 16049014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Berberine attenuates hypoxia-induced pulmonary arterial hypertension via bone morphogenetic protein and transforming growth factor-β signaling.
    Chen M; Shen H; Zhu L; Yang H; Ye P; Liu P; Gu Y; Chen S
    J Cell Physiol; 2019 Aug; 234(10):17482-17493. PubMed ID: 30786011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An emerging class of new therapeutics targeting TGF, Activin, and BMP ligands in pulmonary arterial hypertension.
    Upton PD; Dunmore BJ; Li W; Morrell NW
    Dev Dyn; 2023 Mar; 252(3):327-342. PubMed ID: 35434863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of novel activin-targeted therapeutics.
    Chen JL; Walton KL; Al-Musawi SL; Kelly EK; Qian H; La M; Lu L; Lovrecz G; Ziemann M; Lazarus R; El-Osta A; Gregorevic P; Harrison CA
    Mol Ther; 2015 Mar; 23(3):434-44. PubMed ID: 25399825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone morphogenic protein-9 stimulates endothelin-1 release from human pulmonary microvascular endothelial cells: a potential mechanism for elevated ET-1 levels in pulmonary arterial hypertension.
    Star GP; Giovinazzo M; Langleben D
    Microvasc Res; 2010 Dec; 80(3):349-54. PubMed ID: 20594999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ligand trap for the activin type IIA receptor protects against vascular disease and renal fibrosis in mice with chronic kidney disease.
    Agapova OA; Fang Y; Sugatani T; Seifert ME; Hruska KA
    Kidney Int; 2016 Jun; 89(6):1231-43. PubMed ID: 27165838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth differentiation factor-9 signaling is mediated by the type I receptor, activin receptor-like kinase 5.
    Mazerbourg S; Klein C; Roh J; Kaivo-Oja N; Mottershead DG; Korchynskyi O; Ritvos O; Hsueh AJ
    Mol Endocrinol; 2004 Mar; 18(3):653-65. PubMed ID: 14684852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repulsive guidance molecule RGMa alters utilization of bone morphogenetic protein (BMP) type II receptors by BMP2 and BMP4.
    Xia Y; Yu PB; Sidis Y; Beppu H; Bloch KD; Schneyer AL; Lin HY
    J Biol Chem; 2007 Jun; 282(25):18129-18140. PubMed ID: 17472960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone morphogenetic protein-3b (BMP-3b) inhibits osteoblast differentiation via Smad2/3 pathway by counteracting Smad1/5/8 signaling.
    Matsumoto Y; Otsuka F; Hino J; Miyoshi T; Takano M; Miyazato M; Makino H; Kangawa K
    Mol Cell Endocrinol; 2012 Mar; 350(1):78-86. PubMed ID: 22155034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone Morphogenetic Protein 9 Is a Mechanistic Biomarker of Portopulmonary Hypertension.
    Nikolic I; Yung LM; Yang P; Malhotra R; Paskin-Flerlage SD; Dinter T; Bocobo GA; Tumelty KE; Faugno AJ; Troncone L; McNeil ME; Huang X; Coser KR; Lai CSC; Upton PD; Goumans MJ; Zamanian RT; Elliott CG; Lee A; Zheng W; Berasi SP; Huard C; Morrell NW; Chung RT; Channick RW; Roberts KE; Yu PB
    Am J Respir Crit Care Med; 2019 Apr; 199(7):891-902. PubMed ID: 30312106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.